Close Menu

NEW YORK (GenomeWeb) – Joshua LaBaer, executive director of Arizona State University's Biodesign Institute, is launching a company to commercialize his lab's Nucleic Acid Programmable Protein Array (NAPPA) technology.

Named Ordinatrix, the Phoenix, Arizona-based company will sell the NAPPA platform as a research tool and offer research services using the system, LaBaer said, noting that it plans to begin sales in July.

The company has appointed Jim Hauert, former executive at ADMA Biologics and Baxter Bioscience, as president and CEO, while LaBaer is a board member.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.